SIM0235
/ Simcere
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
July 27, 2023
SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): Preliminary results from an on-going first-in-human phase I trial in China
(ESMO 2023)
- P1 | "The preliminary PK and PD results support every 3-week dosing at 40mg/kg as the recommended dose for expansion. The clinical development of SIM1811-03 in combination with immunotherapy is planned."
Clinical • Metastases • P1 data • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma • CD14 • TNFA • TNFRSF1B
September 21, 2023
A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors
(clinicaltrials.gov)
- P1 | N=255 | Recruiting | Sponsor: Jiangsu Simcere Biologics Co., Ltd | N=120 ➔ 255
Enrollment change • Metastases • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Skin Cancer • Solid Tumor • T Cell Non-Hodgkin Lymphoma
March 14, 2023
Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma
(PRNewswire)
- "Simcere Pharmaceutical Group Limited...announced today that Simcere Zaiming, an innovative oncology pharmaceutical company of Simcere has entered into a clinical collaboration agreement with MSD...to evaluate the combination of SIM0235, a potential first-in-class humanized anti-tumor necrosis factor receptor 2 (TNFR2) monoclonal antibody, and MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors and cutaneous T-cell lymphoma (CTCL). This is a Phase 1 trial (SIM1811-03-TNFR2-102) to evaluate the safety, efficacy, pharmacokinetic/pharmacodynamic characteristics and immunogenicity of SIM0235 monotherapy and SIM0235 in combination with KEYTRUDA in patients with advanced solid tumors and CTCL."
Clinical protocol • Licensing / partnership • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma
March 23, 2023
A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors
(clinicaltrials.gov)
- P1 | N=120 | Recruiting | Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Metastases • New P1 trial • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Skin Cancer • Solid Tumor • T Cell Non-Hodgkin Lymphoma
October 06, 2022
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
(clinicaltrials.gov)
- P1 | N=100 | Recruiting | Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
New P1 trial • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Sezary Syndrome • Skin Cancer • Solid Tumor • T Cell Non-Hodgkin Lymphoma
1 to 5
Of
5
Go to page
1